STOCK TITAN
  1. Home
  2. Sec-filings
  3. FLGT
  4. [Form 4] Fulgent Genetics, Inc. Insider Trading Activity

Fulgent Genetics (NASDAQ: FLGT) CSO sells 939 shares to cover taxes

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Fulgent Genetics, Inc. (FLGT) reported that Chief Scientific Officer Hanlin Gao sold 939 shares of common stock on August 27, 2026, in an open-market transaction at a weighted-average price of $19.9053 per share, in multiple trades between $19.83 and $20.00. According to the disclosure, the sale was made to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 26, 2024. Following this sale, Gao directly holds 987,790 shares of Fulgent Genetics common stock.

Positive

  • None.

Negative

  • None.
Insider Gao Hanlin
Role Chief Scientific Officer
Sold 939 shs ($19K)
Type Security Shares Price Value
Sale Common Stock F1, F2 939 $19.9053 $19K
Holdings After Transaction: Common Stock — 987,790 shares (Direct)
Footnotes (2)
  1. F1. The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024.
  2. F2. The shares were sold in multiple transactions at prices ranging from $19.83 to $20.00, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
Shares sold 939 shares of Common Stock Open-market sale on August 27, 2026
Weighted-average sale price $19.9053 per share Sale of 939 shares on August 27, 2026
Post-transaction holdings 987,790 shares of Common Stock Direct ownership after the August 27, 2026 sale
Sale price range $19.83 to $20.00 per share Multiple transactions comprising the 939-share sale
weighted-average sale price financial
"The shares were sold in multiple transactions at prices ranging from $19.83 to $20.00, inclusive. The reported price reflects the weighted-average sale price."
restricted stock units financial
"tax withholding obligations that arose upon the vesting of certain restricted stock units granted"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
tax withholding obligations financial
"shares were sold by the reporting person to satisfy the tax withholding obligations that arose"

FAQ

What insider transaction did FLGT report for Hanlin Gao?
Fulgent Genetics reported that Chief Scientific Officer Hanlin Gao sold 939 shares of common stock on August 27, 2026 at a weighted-average price of $19.9053 per share in multiple trades between $19.83 and $20.00.

Why did Hanlin Gao sell shares of FLGT stock?
The filing states that the 939 shares were sold to satisfy tax withholding obligations that arose when certain restricted stock units granted to Hanlin Gao on February 26, 2024 vested.

How many FLGT shares does Hanlin Gao hold after this transaction?
After the August 27, 2026 sale, Hanlin Gao directly holds 987,790 shares of Fulgent Genetics common stock, as reported in the Form 4.

At what prices were Hanlin Gao’s FLGT shares sold?
The shares were sold in multiple transactions at prices ranging from $19.83 to $20.00 per share. The Form 4 reports a weighted-average sale price of $19.9053 per share for the 939 shares sold.

Was Hanlin Gao’s FLGT trade under a Rule 10b5-1 trading plan?
The document-level Rule 10b5-1 checkbox is not checked, and the footnotes do not state that the sale was made pursuant to a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gao Hanlin
(Last)(First)(Middle)
C/O FULGENT GENETICS, INC.
4399 SANTA ANITA AVENUE
(Street)
EL MONTE CALIFORNIA 91731
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Scientific Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/27/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/27/2026S939(1)D$19.9053(2)987,790D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024.
2. The shares were sold in multiple transactions at prices ranging from $19.83 to $20.00, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
/s/ Paul Kim as Attorney-in-Fact08/28/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR